| 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] | Technology appraisal guidance |
| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Abdominal aortic aneurysm | Quality standard |
| Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Acne | Quality standard |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Adrenal dysfunction | Quality standard |
| Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care | Quality standard |
| Advocacy services for adults with health and social care needs | Quality standard |
| Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064] | Technology appraisal guidance |
| AI and novel technologies in lung function measurement | Health technology evaluation |
| Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] | Technology appraisal guidance |
| Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036] | Technology appraisal guidance |
| Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Technology appraisal guidance |
| Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471] | Technology appraisal guidance |
| Apraglutide for treating short bowel syndrome
[ID6533] | Technology appraisal guidance |
| Aprocitentan for treating resistant hypertension [TSID10395] | Technology appraisal guidance |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | Medical technologies guidance |
| Artificial intelligence technologies for mammography: early value assessment | Health technology evaluation |
| Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease
[ID6524] | Technology appraisal guidance |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894] | Technology appraisal guidance |
| Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515] | Technology appraisal guidance |
| Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401] | Technology appraisal guidance |
| Balloon cryoablation for Barrett's oesophagus | Interventional procedures guidance |
| Baloxavir marboxil for Influenza | Technology appraisal guidance |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years
[TSID12142] | Technology appraisal guidance |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance |
| Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476] | Technology appraisal guidance |
| Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] | Technology appraisal guidance |
| Benralizumab for previously treated severe nasal polyps [ID1659] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322] | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344] | Technology appraisal guidance |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537] | Technology appraisal guidance |
| BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] | Technology appraisal guidance |
| Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384] | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis [TSID10334] | Technology appraisal guidance |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991] | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592] | Technology appraisal guidance |
| Botulinum toxin type A for preventing episodic migraine [ID6450] | Technology appraisal guidance |
| Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448] | Technology appraisal guidance |
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437] | Technology appraisal guidance |
| Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486] | Technology appraisal guidance |
| Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [TSID12082] | Technology appraisal guidance |
| Bupivacaine–meloxicam for treating postoperative pain [ID2728] | Technology appraisal guidance |
| Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] | Technology appraisal guidance |
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |
| CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210] | Technology appraisal guidance |
| Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation
[ID6535] | Technology appraisal guidance |
| Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534] | Technology appraisal guidance |
| Camlipixant for treating refractory or unexplained chronic cough [TSID12072] | Technology appraisal guidance |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888] | Technology appraisal guidance |
| Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466] | Technology appraisal guidance |
| Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214] | Technology appraisal guidance |
| Children and young people with disabilities and severe complex needs: integrated health and social care support | Quality standard |
| Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136] | Technology appraisal guidance |
| Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099] | Technology appraisal guidance |
| Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417] | Technology appraisal guidance |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839] | Technology appraisal guidance |
| Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838] | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522] | Technology appraisal guidance |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449] | Technology appraisal guidance |
| Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [TSID10392] | Technology appraisal guidance |
| Deucravacitinib for treating active psoriatic arthritis [TSID11981] | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154] | Technology appraisal guidance |
| Digital platforms to support self-management of asthma : early value assessment | Health technology evaluation |
| Diverticular disease | Quality standard |
| Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457] | Technology appraisal guidance |
| Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521] | Technology appraisal guidance |
| Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [TSID12115] | Technology appraisal guidance |
| Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311] | Technology appraisal guidance |
| Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426] | Technology appraisal guidance |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484] | Highly specialised technology |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046] | Technology appraisal guidance |
| Dulaglutide for treating type 2 diabetes [ID1451] | Technology appraisal guidance |
| Dupilumab for treating bullous pemphigoid [ID6479] | Technology appraisal guidance |
| Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492] | Technology appraisal guidance |
| Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736] | Technology appraisal guidance |
| Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206] | Technology appraisal guidance |
| Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374] | Technology appraisal guidance |
| Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254] | Technology appraisal guidance |
| Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080] | Technology appraisal guidance |
| Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944] | Technology appraisal guidance |
| Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146] | Technology appraisal guidance |
| Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445] | Technology appraisal guidance |
| Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428] | Technology appraisal guidance |
| Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124] | Technology appraisal guidance |
| Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855] | Technology appraisal guidance |
| Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830] | Technology appraisal guidance |
| Edaravone for treating amyotrophic lateral sclerosis [TSID11869] | Technology appraisal guidance |
| Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046] | Technology appraisal guidance |
| Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [ID6532] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [TSID12145] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [TSID12146] | Technology appraisal guidance |
| Ensitrelvir for treating COVID 19 [ID6231] | Technology appraisal guidance |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463] | Technology appraisal guidance |
| Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015] | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037] | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278] | Technology appraisal guidance |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Galcanezumab for migraine [TSID10663] | Technology appraisal guidance |
| Gambling | Quality standard |
| Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126] | Technology appraisal guidance |
| Gantenerumab for treating early Alzheimer's disease [TSID10668] | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Gout | Quality standard |
| Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071] | Technology appraisal guidance |
| Heart valve disease in adults | Quality standard |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747] | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies [ID6491] | Technology appraisal guidance |
| Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376] | Technology appraisal guidance |
| In-situ Normothermic Regional Perfusion system for DCD donors - liver | Interventional procedures guidance |
| Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over
[TSID12144] | Technology appraisal guidance |
| Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129] | Technology appraisal guidance |
| Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430] | Technology appraisal guidance |
| Inebilizumab for treating generalised myasthenia gravis
[TSID12110] | Technology appraisal guidance |
| Inebilizumab for treating immunoglobulin G4-related disease
[TSID12107] | Technology appraisal guidance |
| Infant, children and young people's experience of health care | Quality standard |
| Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923] | Technology appraisal guidance |
| Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure | Interventional procedures guidance |
| Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498] | Technology appraisal guidance |
| Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499] | Technology appraisal guidance |
| Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage | Interventional procedures guidance |
| Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190] | Technology appraisal guidance |
| Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469] | Technology appraisal guidance |
| Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949] | Technology appraisal guidance |
| Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868] | Technology appraisal guidance |
| Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] | Technology appraisal guidance |
| Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292] | Technology appraisal guidance |
| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305] | Technology appraisal guidance |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance |
| Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996] | Technology appraisal guidance |
| Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652] | Technology appraisal guidance |
| Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265] | Technology appraisal guidance |
| Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869] | Technology appraisal guidance |
| Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer PD [ID6526] | Technology appraisal guidance |
| Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870] | Technology appraisal guidance |
| Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315] | Technology appraisal guidance |
| Machine perfusion devices for liver transplant | Health technology evaluation |
| Managing symptoms with an uncertain cause | Quality standard |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy
[TSID12143] | Technology appraisal guidance |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728 | Technology appraisal guidance |
| Mavorixafor for treating WHIM syndrome [ID3946] | Technology appraisal guidance |
| Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237] | Technology appraisal guidance |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513] | Technology appraisal guidance |
| MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400] | Technology appraisal guidance |
| Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730] | Technology appraisal guidance |
| Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538] | Technology appraisal guidance |
| Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769] | Technology appraisal guidance |
| Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777] | Technology appraisal guidance |
| Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078] | Technology appraisal guidance |
| Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TSID12048] | Technology appraisal guidance |
| Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593] | Technology appraisal guidance |
| Nipocalimab for treating generalised myasthenia gravis [TSID11958] | Technology appraisal guidance |
| Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [TSID12044] | Technology appraisal guidance |
| Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316] | Technology appraisal guidance |
| Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345] | Technology appraisal guidance |
| Nirogacestat for treating desmoid tumours [ID6453] | Technology appraisal guidance |
| Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321] | Technology appraisal guidance |
| Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659] | Technology appraisal guidance |
| Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239] | Technology appraisal guidance |
| Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475] | Technology appraisal guidance |
| Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519] | Technology appraisal guidance |
| Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996] | Technology appraisal guidance |
| Olezarsen for treating familial chylomicronaemia
syndrome [TSID11993] | Technology appraisal guidance |
| Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912] | Technology appraisal guidance |
| Ondansetron for treating alcohol-use disorder [ID6341] | Technology appraisal guidance |
| Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941 | Technology appraisal guidance |
| Oral semaglutide for managing overweight and obesity [ID6188] | Technology appraisal guidance |
| Orforglipron for managing overweight and obesity [ID6516] | Technology appraisal guidance |
| Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472] | Technology appraisal guidance |
| Osteoporosis | Quality standard |
| OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152] | Highly specialised technology |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Pain management (young people and adults) | Quality standard |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Pancreatitis (including acute pancreatitis) | Quality standard |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865] | Technology appraisal guidance |
| Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467] | Technology appraisal guidance |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance |
| Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Technology appraisal guidance |
| Pelvic floor dysfunction | Quality standard |
| Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021] | Technology appraisal guidance |
| Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994] | Technology appraisal guidance |
| Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477] | Technology appraisal guidance |
| Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [TSID11953] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] | Technology appraisal guidance |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853] | Technology appraisal guidance |
| Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810] | Technology appraisal guidance |
| Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096] | Technology appraisal guidance |
| Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993] | Technology appraisal guidance |
| Pembrolizumab with olaparib and chemoradiation for
previously untreated limited-stage small-cell lung cancer [ID6412] | Technology appraisal guidance |
| Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587] | Technology appraisal guidance |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | Interventional procedures guidance |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | Interventional procedures guidance |
| Perioperative care | Quality standard |
| Pernicious anaemia | Quality standard |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493] | Technology appraisal guidance |
| Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895] | Technology appraisal guidance |
| PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989] | Technology appraisal guidance |
| Prevention of dementia | Quality standard |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| Primary hyperparathyroidism | Quality standard |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130] | Technology appraisal guidance |
| Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512] | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema [ID6137] | Technology appraisal guidance |
| Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642] | Technology appraisal guidance |
| Readmission to ICU within 48hrs | Quality standard |
| REGN5458 for treating relapsed or refractory multiple myeloma [TSID10443] | Technology appraisal guidance |
| Remdesivir for treating COVID 19 [ID3808] | Technology appraisal guidance |
| Remibrutinib for treating chronic spontaneous urticaria
inadequately controlled by H1-antihistamines [ID6356] | Technology appraisal guidance |
| Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147] | Technology appraisal guidance |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] | Technology appraisal guidance |
| Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome [ID6478] | Technology appraisal guidance |
| Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436] | Technology appraisal guidance |
| Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy
[ID6482] | Technology appraisal guidance |
| Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395] | Technology appraisal guidance |
| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Robot-assisted surgery for soft-tissue procedures: early value assessment | Health technology evaluation |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764] | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763] | Technology appraisal guidance |
| Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433] | Technology appraisal guidance |
| Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal | Quality standard |
| Safeguarding adults in care homes | Quality standard |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237] | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454] | Technology appraisal guidance |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance |
| Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib
[ID6494] | Technology appraisal guidance |
| Secondary care management of malignant hypertension | Quality standard |
| Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825] | Technology appraisal guidance |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385] | Technology appraisal guidance |
| Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis [ID6458] | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes [ID1450] | Technology appraisal guidance |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older
[ID6542] | Technology appraisal guidance |
| Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827] | Technology appraisal guidance |
| Shared decision-making: practical guidance for health and social care professionals | Quality standard |
| Sibeprenlimab for treating IgA nephropathy [TSID12111] | Technology appraisal guidance |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147] | Technology appraisal guidance |
| Sleep disordered breathing | Quality standard |
| Social work interventions for adults with complex needs (including learning disabilities) and mental health needs | Quality standard |
| Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536] | Technology appraisal guidance |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions | Medical technologies guidance |
| Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086] | Technology appraisal guidance |
| STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278] | Technology appraisal guidance |
| STS101 for treating acute migraine [TSID11782] | Technology appraisal guidance |
| Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977] | Technology appraisal guidance |
| Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081 | Technology appraisal guidance |
| Superior rectal artery embolisation for haemorrhoids | Interventional procedures guidance |
| Supporting independent living and preventing isolation in adults of working age with social care needs | Quality standard |
| Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments [ID6413] | Technology appraisal guidance |
| Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460] | Technology appraisal guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918] | Technology appraisal guidance |
| The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound | Medical technologies guidance |
| Thyroid disease | Quality standard |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tinnitus | Quality standard |
| Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217] | Technology appraisal guidance |
| Tirzepatide for treating type 2 diabetes in people 10 to 17 years
[TSID12131] | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683] | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158] | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis [ID1396] | Technology appraisal guidance |
| Tolebrutinib for treating relapsing multiple sclerosis [ID6351] | Technology appraisal guidance |
| Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406] | Technology appraisal guidance |
| Tovorafenib for Glioma (rare disease) [TSID12140] | Technology appraisal guidance |
| Trans-venous embolisation for the treatment of Cerebrospinal fluid venous fistula (CSFVF) a cause of spontaneous intracranial hypotension (SIH) | Interventional procedures guidance |
| Transcatheter tricuspid valve implantation for tricuspid regurgitation | Interventional procedures guidance |
| Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509] | Technology appraisal guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [TSID11910] | Technology appraisal guidance |
| Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [TSID12104] | Technology appraisal guidance |
| Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318] | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772] | Technology appraisal guidance |
| Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891] | Technology appraisal guidance |
| Troriluzole for spinocerebellar ataxia [ID6456] | Technology appraisal guidance |
| Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] | Technology appraisal guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781] | Technology appraisal guidance |
| UX111 for treating mucopolysaccharidosis type IIIA [TSID 12124] | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] | Technology appraisal guidance |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295] | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |
| Vulnerable populations: strategies for tackling inequalities | Quality standard |
| WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467] | Technology appraisal guidance |
| Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477] | Technology appraisal guidance |
| Zavegepant for treating acute migraine
[TSID11998] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults | Interventional procedures guidance |